Please wait while the formulary information is being retrieved.
CAYSTON (AZTREONAM LYSINE)
- Respiratory cystic fibrosis p. aeruginosa colonization
75 mg/mL solution for nebulization
- Inhale 1 milliliter (75 mg) via nebulizer by inhalation route 3 timesper day for 28 days
Respiratory cystic fibrosis p. aeruginosa colonization
- Inhale 1 milliliter (75 mg) via nebulizer by inhalation route 3 timesper day
- Inhale 1 milliliter (75 mg) via nebulizer by inhalation route 3 timesper day for 28 days
- typhoid vaccine
- Vivotif Berna Vaccine
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Bronchospastic pulmonary disease
CAYSTON (AZTREONAM LYSINE)
- Respiratory cystic fibrosis p. aeruginosa colonization
- None
- Acute abdominal pain
- Chest discomfort
- Cough
- Fever
- Nasal congestion
- Vomiting
- Wheezing
More Frequent
Severe
Less Severe
- None
- Bronchospastic pulmonary disease
- Sore throat
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Dyspnea
- Facial edema
- Skin rash
- Throat constriction
Less Severe
- Arthralgias
- Arthritis
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Aztreonam (Inh)
Safety and efficacy not established age < 7 years.
- 1 Day – 7 Years
- Safety and efficacy not established age < 7 years.
Aztreonam
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Aztreonam (inhalation)
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory cystic fibrosis p. aeruginosa colonization | |
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
| 0-9 | A-Z |
|---|---|
| B96.5 | Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
Formulary Reference Tool